Complement activation in vivo in cancer patients receiving C. parvum immunotherapy.

Serum complement levels were assayed in 26 patients with disseminated cancer, who received immunotherapy with infusion of C. parvum. Complement activation, indicated by the consumption of C3 or C4 or both, was found in 46% of the patients. Serum samples showed direct correlation between decreased C3...

Descripción completa

Detalles Bibliográficos
Autores principales: Biran, H., Moake, J. L., Reed, R. C., Gutterman, J. U., Hersh, E. M., Freireich, E. J., Mavligit, G. M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1976
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2025195/
https://www.ncbi.nlm.nih.gov/pubmed/999783
_version_ 1782136715680415744
author Biran, H.
Moake, J. L.
Reed, R. C.
Gutterman, J. U.
Hersh, E. M.
Freireich, E. J.
Mavligit, G. M.
author_facet Biran, H.
Moake, J. L.
Reed, R. C.
Gutterman, J. U.
Hersh, E. M.
Freireich, E. J.
Mavligit, G. M.
author_sort Biran, H.
collection PubMed
description Serum complement levels were assayed in 26 patients with disseminated cancer, who received immunotherapy with infusion of C. parvum. Complement activation, indicated by the consumption of C3 or C4 or both, was found in 46% of the patients. Serum samples showed direct correlation between decreased C3 and conversion of C3 proactivator, whereas such conversion did not occur when C4 alone was decreased. It is concluded that the bypass (properdin) pathway was activated in patients in whom C3 consumption was detected, while the classical (C1) pathway was activated in the patients with C4 consumption unaccompanied by C3 decrease. Direct correlation was observed between delayed cutaneous hypersensitivity reactions to recall antigens and the incidence of C. parvum-associated complement activation.
format Text
id pubmed-2025195
institution National Center for Biotechnology Information
language English
publishDate 1976
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20251952009-09-10 Complement activation in vivo in cancer patients receiving C. parvum immunotherapy. Biran, H. Moake, J. L. Reed, R. C. Gutterman, J. U. Hersh, E. M. Freireich, E. J. Mavligit, G. M. Br J Cancer Research Article Serum complement levels were assayed in 26 patients with disseminated cancer, who received immunotherapy with infusion of C. parvum. Complement activation, indicated by the consumption of C3 or C4 or both, was found in 46% of the patients. Serum samples showed direct correlation between decreased C3 and conversion of C3 proactivator, whereas such conversion did not occur when C4 alone was decreased. It is concluded that the bypass (properdin) pathway was activated in patients in whom C3 consumption was detected, while the classical (C1) pathway was activated in the patients with C4 consumption unaccompanied by C3 decrease. Direct correlation was observed between delayed cutaneous hypersensitivity reactions to recall antigens and the incidence of C. parvum-associated complement activation. Nature Publishing Group 1976-11 /pmc/articles/PMC2025195/ /pubmed/999783 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Biran, H.
Moake, J. L.
Reed, R. C.
Gutterman, J. U.
Hersh, E. M.
Freireich, E. J.
Mavligit, G. M.
Complement activation in vivo in cancer patients receiving C. parvum immunotherapy.
title Complement activation in vivo in cancer patients receiving C. parvum immunotherapy.
title_full Complement activation in vivo in cancer patients receiving C. parvum immunotherapy.
title_fullStr Complement activation in vivo in cancer patients receiving C. parvum immunotherapy.
title_full_unstemmed Complement activation in vivo in cancer patients receiving C. parvum immunotherapy.
title_short Complement activation in vivo in cancer patients receiving C. parvum immunotherapy.
title_sort complement activation in vivo in cancer patients receiving c. parvum immunotherapy.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2025195/
https://www.ncbi.nlm.nih.gov/pubmed/999783
work_keys_str_mv AT biranh complementactivationinvivoincancerpatientsreceivingcparvumimmunotherapy
AT moakejl complementactivationinvivoincancerpatientsreceivingcparvumimmunotherapy
AT reedrc complementactivationinvivoincancerpatientsreceivingcparvumimmunotherapy
AT guttermanju complementactivationinvivoincancerpatientsreceivingcparvumimmunotherapy
AT hershem complementactivationinvivoincancerpatientsreceivingcparvumimmunotherapy
AT freireichej complementactivationinvivoincancerpatientsreceivingcparvumimmunotherapy
AT mavligitgm complementactivationinvivoincancerpatientsreceivingcparvumimmunotherapy

Ejemplares similares